“…The conversion of the amine-type endocyclic nitrogen of iminosugars into a pseudoamide-type functionality, with high sp 2 -hybridation character (sp 2 -iminosugars) [ 21 , 22 ], has demonstrated to be a very promising strategy to improve both parameters, with several sp 2 -iminosugar representatives under investigational or preclinical development for the LSDs Gaucher [ 23 , 24 , 25 , 26 , 27 ], Fabry [ 28 ], G M1 -gangliosidosis [ 29 , 30 ], and Tay-Sachs diseases [ 31 ]. The glycosidase inhibitory and chaperoning abilities of sp 2 -iminosugars have been found to be strongly dependent on the mono- [ 32 , 33 , 34 , 35 , 36 ] or bicyclic structure of the sugar glycone-like skeleton [ 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ], the configurational pattern [ 45 , 46 , 47 , 48 ], and the nature of nonglycone-type substituents [ 49 , 50 , 51 ]. Differently from classical iminosugars, for which the lability of aminal functionalities prevents the installation of anomeric substituents (except in the case of pseudo- C -glycosides) [ 52 , 53 , 54 , 55 ], sp 2 -iminosugars can bear O -, S -, N -, or C -anomeric aglycone groups while keeping full chemical and configurational stability [ 56 , 57 , 58 , 59 , 60 , ...…”